These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34915496)

  • 41. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
    Kritikos V; Harvey ES; Stevens S; Katelaris CH; Langton D; Rimmer J; Farah CS; Gillman A; Hew M; Radhakrishna N; Thomas D; Gibson PG;
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):885-895.e13. PubMed ID: 36572182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.
    Renner A; Marth K; Patocka K; Idzko M; Pohl W
    Pulm Pharmacol Ther; 2020 Oct; 64():101946. PubMed ID: 32949705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study.
    Crimi C; Campisi R; Nolasco S; Cacopardo G; Intravaia R; Porto M; Impellizzeri P; Pelaia C; Crimi N
    Respir Med; 2021; 185():106491. PubMed ID: 34098492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
    Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
    Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 51. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
    Yancey SW; Bradford ES; Keene ON
    Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab.
    Atayık E; Aytekin G
    Turk Thorac J; 2022 Sep; 23(5):348-354. PubMed ID: 35957566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
    Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis.
    Li H; Zhang Q; Wang J; Gao S; Li C; Wang J; Zhang S; Lin J
    Clin Ther; 2021 Jun; 43(6):e192-e208. PubMed ID: 33962763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The long-term outcomes of mepolizumab treatment at 100 mg dose on idiopathic chronic eosinophilic pneumonia: A real-life experience.
    Vural Solak GT; Aksu K; Akkale O; Telli O; Celik Tuglu H; Dindar Celik F; Yagdiran M
    Allergy Asthma Proc; 2024 Jul; 45(4):e46-e53. PubMed ID: 38982601
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
    Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.
    Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
    Respir Investig; 2021 Jul; 59(4):478-486. PubMed ID: 33849780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
    Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.